Gastric Inhibitory Peptide (GIP): What It Does in the Body

Gastric inhibitory peptide (GIP) is a hormone released by the upper small intestine after you eat, and its main job is to help the pancreas release insulin when blood sugar rises. It is one of the two incretin hormones, alongside glucagon-like peptide-1 (GLP-1). GIP also acts on fat tissue, bone, and the brain, which is why it has become a major target in diabetes and obesity research.

Despite the name, GIP does not meaningfully block stomach acid at normal levels in humans. Researchers renamed it glucose-dependent insulinotropic polypeptide to reflect what it actually does.

What Is Gastric Inhibitory Peptide?

GIP is a 42-amino-acid peptide made by K cells that line the duodenum and jejunum, the first sections of the small intestine. Blood levels stay low in the fasting state and jump within minutes of eating, especially after carbohydrates and fat.

The hormone binds to GIP receptors on pancreatic beta cells, fat cells, bone-forming cells, and parts of the brain. An enzyme called DPP-4 breaks GIP down within minutes, so its signal is short-lived.

• Source: K cells in the upper small intestine
• Release trigger: food, especially glucose and fat
• Main known action: glucose-dependent insulin release
• Half-life: roughly 5 to 7 minutes in the bloodstream
• Also called: glucose-dependent insulinotropic polypeptide

How GIP Works After a Meal

GIP enters the bloodstream as food reaches the gut, and it coordinates several responses at once.

1. Insulin release. GIP tells beta cells to release insulin, but only when blood glucose is already elevated. That glucose dependence is why GIP alone does not cause low blood sugar.
2. Glucagon signaling. GIP also stimulates glucagon release from alpha cells, an effect that differs from GLP-1.
3. Fat storage. GIP receptors on fat tissue promote fat uptake and storage after a meal.
4. Bone and brain effects. GIP receptors appear in bone and the central nervous system, and studies link GIP signaling to bone formation and satiety cues.

In people with type 2 diabetes, GIP levels are often normal or even high, but the pancreas responds less strongly to the hormone. That reduced sensitivity helped push drug developers toward combining GIP and GLP-1 activity in a single molecule.

GIP vs. GLP-1: How the Two Incretins Compare

GIP and GLP-1 are both incretins, meaning they amplify insulin release after meals, but they behave differently in almost every other way.

Feature	GIP	GLP-1
Source cells	K cells, upper small intestine	L cells, lower small intestine and colon
Insulin release	Yes, glucose-dependent	Yes, glucose-dependent
Effect on glucagon	Stimulates	Suppresses
Gastric emptying	Minimal effect	Slows it noticeably
Appetite	Little direct effect	Reduces appetite
Drug examples	Tirzepatide (with GLP-1 activity)	Semaglutide, dulaglutide, liraglutide

One common question is what does glucagon-like peptide 1 do that GIP does not: GLP-1 slows stomach emptying and signals fullness more strongly. That difference is why the first blockbuster weight-loss drugs targeted GLP-1 alone.

GIP in Diabetes and Weight-Loss Medications

The most important clinical advance involving GIP is tirzepatide, a dual GIP and GLP-1 receptor agonist sold as Mounjaro for type 2 diabetes and Zepbound for weight management. In clinical trials, tirzepatide produced larger drops in A1c and body weight than GLP-1-only drugs at comparable doses.

Researchers are also testing the opposite strategy: GIP receptor antagonists that block the hormone rather than activate it. Early human data suggest blocking GIP may improve glucose control and reduce weight, but this approach remains experimental.

It is worth noting that a glucagon-like peptide-1 supplement sold online is not the same thing as a prescription incretin drug. Those oral products typically contain amino acids or plant extracts, not active GLP-1 or GIP.

For comparison, the aod9604 peptide is a fragment of human growth hormone studied for fat metabolism, and it works through entirely different biology than GIP.

What GIP Is Not: Skin, Hair, and Gray-Market Peptides

GIP is a gut hormone, so it has nothing to do with the topical peptides sold for skin and hair. Products marketed as the best peptide cream dermatologist offices recommend usually rely on copper peptides or matrixyl, which act on the skin surface.

The same logic applies to a peptide for hair growth: those formulas target hair follicles from the outside, not incretin receptors in the gut.

GIP is not an FDA-approved supplement ingredient, and no over-the-counter product has been shown to raise active GIP levels in a meaningful way. Oral peptides are largely broken down in the stomach before they ever reach the bloodstream.

Safety and When to Talk to a Healthcare Professional

Prescription drugs that activate the GIP receptor can cause nausea, vomiting, diarrhea, constipation, and injection-site reactions. Serious but uncommon risks include gallbladder disease and pancreatitis.

Anyone considering an incretin-based medication should discuss personal risk factors, medication interactions, and monitoring with a healthcare professional. This article is informational only and is not medical advice.

COMMON QUESTIONS

Frequently Asked Questions

What does gastric inhibitory peptide do?

GIP is released by the small intestine after you eat and signals the pancreas to release insulin when blood glucose is high. It also acts on fat tissue, bone, and the brain. Because its insulin effect depends on existing glucose, GIP does not cause hypoglycemia on its own.

Is gastric inhibitory peptide the same as GLP-1?

No. GIP comes from K cells in the upper small intestine, while GLP-1 comes from L cells lower in the gut. GLP-1 slows stomach emptying and suppresses glucagon, while GIP stimulates glucagon and has little effect on appetite.

Can you buy gastric inhibitory peptide as a supplement?

No over-the-counter GIP supplement is FDA-approved to treat diabetes or obesity, and oral peptides are mostly digested before they reach the bloodstream. The only FDA-approved medicine that targets the GIP receptor is prescription tirzepatide, which also activates GLP-1 receptors.